• KOL
    • Parkinson Disease
    • Christopher G Goetz
    • Christopher G Goetz: Influence Statistics

      Christopher G Goetz

      Christopher G Goetz

      Show email address

      Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA. | Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Christopher G Goetz:Expert Impact

      Concepts for whichChristopher G Goetzhas direct influence:Parkinson disease,Parkinsons disease,Movement disorders,Rating scales,Rating scale,Motor fluctuations,Task force,Movement disorder.

      Christopher G Goetz:KOL impact

      Concepts related to the work of other authors for whichfor which Christopher G Goetz has influence:Parkinson disease,Cognitive impairment,Lewy bodies,Motor symptoms,Movement disorders,Progressive supranuclear,Tourette syndrome.

      KOL Resume for Christopher G Goetz

      Year
      2022

      Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.

      Rush University Medical Center, Chicago, Illinois, USA

      2021

      Department of Neurological Sciences, Section of Movement Disorders, Rush University Medical Center, Chicago, Illinois, USA

      2020

      Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, Chicago, United States.

      2019

      From the Departments of Neurology (M.A.S., R.B., S.B., R.L., A.Y.H., G.B.) and Medicine (E.A.M.), Massachusetts General Hospital, Boston; University of Cincinnati (A.J.E.), OH; Rush University (C.G.G.), Chicago, IL; Michigan State University (J.L.G.), East Lansing; Struthers Parkinson's Center (S.A.P.), Minneapolis, MN; Boston University (M.H.S.-H.), MA; University of Rochester (A.R.), NY; University of Miami (J.M.H.), FL; Brigham and Women’s Hospital (G.C.C.), Boston, MA; Yale University School of Medicine (D.S.R.), New Haven, CT; and Department of Nutrition (A.A.), Harvard School of Public Health, Boston, MA

      Department of Neurological Sciences and Pediatrics, Rush University, Chicago, Illinois, United States

      2018

      Dept. of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA

      Rush University Medical Center, Chicago, IL, United States

      2017

      Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois

      2016

      Rush University Medical Center, Chicago, IL, USA

      2015

      Rush University Medical Center Department of Neurological Sciences

      2014

      Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.

      Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch‐Belval, Luxembourg

      Rush University Medical Center Chicago IL USA

      2013

      Rush University Medical Center Department of Neurological Sciences Section of Movement Disorders Chicago Illinois USA

      2012

      Rush University Medical Center, Chicago, IL 60612, USA; Suite 755, 1725 W. Harrison Street, Chicago, IL 60612, USA

      2011

      Rush University Medical Center, Department of Neurological Sciences, 1725 W. Harrison Street, Suite 755, Chicago, IL 60612 USA +1 312 563 2900; +1 312 563 2024;

      Suite 755, 1725 W. Harrison St., Chicago, IL 60612 USA

      2010

      Suite 755, 1725 W. Harrison Street, Chicago, IL 60612

      From the Department of Neurological Sciences, Rush University Medical Center, Chicago, IL.

      Department of Pharmacology, Rush University Medical Center, Chicago, Illinois, USA

      Statistical analysis was performed by G.T. Stebbins and W. Fan, Rush University Medical Center, Chicago, Illinois.

      Rush University, Chicago, Illinois (Drs Goetz and Stebbins).

      2009

      Department of Neurosciences, Rush University Medical Center, Chicago, Illinois, USA

      2008

      Department of Neurological Sciences, Rush‐Presbyterian St. Luke's Medical Center, Chicago, Illinois, USA

      1725 W. Harrison Street, Suite 755, Chicago, IL 60612

      2007

      From the Department of Neurology, University of Colorado at Denver and Health Sciences Center, Denver, CO (M.A.L., D.A.H.); Neurological Sciences, Pediatrics and Biochemistry, RUSH University Medical Center, Chicago, IL (E.B-K., R.L.); Neurological Sciences, RUSH University Medical Center, Chicago, IL (C.G.G.); Department of Neurology, University of California at Davis Medical Center, Sacramento, CA (L.Z.); Department of Statistics, North Carolina State University, Raleigh, NC (L.L.); Department of Pediatrics, University of Colorado at Denver and Health Sciences Center, Denver, CO (C.D.R., A.R.); Department of Pediatrics, University of California at Davis Medical Center and the M.I.N.D. Institute, Sacramento, CA (J.C., L.G., R.J.H.); Service de Génétique, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (S.J.); Department of Biochemistry and Molecular Medicine, University of California at Davis School of Medicine, Davis, CA (F.T., P.J.H.); Department of Medicine, University of Colorado at Denver and Health Sciences Center, Denver, CO (J.G.).

      Rush Medical College, Rush University Medical Center, Chicago, Illinois

      2006

      Department of Neurological Sciences, RUSH University Medical Center, Chicago, Illinois

      1725 W. Harrison Street, Chicago, IL 60612

      From Rush University Medical Center (C.G.G.), Chicago, IL; and University of Rochester (S.R.S., S.W.E., D.O., I.S.), Rochester, NY.

      2005

      Dept of Neurological Sciences, Rush University’s Medical Center, Chicago, IL, USA

      Department of Pharmacology, Rush University/Rush University Medical Center, Chicago, IL

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Christopher G Goetz is among the top experts in the world.
      Concept World rank
      neurological specialty #1
      pdnc ess scores #1
      2 dimensions phases #1
      gifted intellect #1
      striatal cholinergic input #1
      risk worsened psychosis #1
      scale essential components #1
      ipx054 ld #1
      midposition reduction #1
      anatomoclinical method #1
      visual tests controls #1
      95 gbadbs subjects #1
      spite patient training #1
      madrazo multicenter studies #1
      geste emg amplitude #1
      15 controversies #1
      ahtd patients #1
      dyskinesia scale #1
      chromogranin ventricular fluid #1
      dopamine receptors hydroxylase #1
      etilevodopacarbidopa #1
      animals antimuscarinic agents #1
      parkinsonian impairment progression #1
      pdmas #1
      crst updrs #1
      pdnc cutoff scores #1
      objective dyskinesia #1
      olanzapine parkinsonism #1
      early hallucinations #1
      translated english #1
      placebocontrolled trials subjects #1
      behaviors sleep fragmentation #1
      life screening instruments #1
      disorder tremor #1
      ziprasidone treatment children #1
      improvements tic disability #1
      placebocontrolled trials patients #1
      clinical characteristics addition #1
      hallucinations allele frequency #1
      pdq8 mdsupdrs #1
      ld levels #1
      updrs parts mdsupdrs #1
      apomorphine agonist administration #1
      disease hallucinations #1
      projectspark #1
      missing values ccc #1
      dnab patients #1
      erc erc atrophy #1
      haloperidol attenuates development #1
      axial gait #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Christopher G Goetz

      KOL-Index: 18409

      Upper and lower gastrointestinal dysautonomia symptoms (GIDS)--sialorrhea, dysphagia, and constipation are common in Parkinson's disease (PD) and often socially as well as physically disabling for patients. Available invasive quantitative measures for assessing these symptoms and their response to therapy are time-consuming, require specialized equipment, can cause patient discomfort and present patients with risk. The Movement Disorders Society commissioned a task force to assess ...

      Known for Rating Scales | Dysphagia Constipation | Task Force | Parkinsons Disease | Movement Disorders
      KOL-Index: 17758

      Depression is a common comorbid condition in Parkinson's disease (PD) and a major contributor to poor quality of life and disability. However, depression can be difficult to assess in patients with PD due to overlapping symptoms and difficulties in the assessment of depression in cognitively impaired patients. As several rating scales have been used to assess depression in PD (dPD), the Movement Disorder Society commissioned a task force to assess their clinimetric properties and make ...

      Known for Rating Scales | Assessment Depression | Dpd Patients | Madrs Bdi | Severity Depressive Symptoms
      KOL-Index: 17171

      The Movement Disorder Society (MDS) Task Force on Evidence-Based Medicine (EBM) Review of Treatments for Parkinson's Disease (PD) was first published in 2002 and was updated in 2005 to cover clinical trial data up to January 2004 with the focus on motor symptoms of PD. In this revised version the MDS task force decided it was necessary to extend the review to non-motor symptoms. The objective of this work was to update previous EBM reviews on treatments for PD with a focus on non-motor ...

      Known for Motor Symptoms | Movement Disorder | Insufficient Evidence | Treatment Psychosis | Medicine Review
      KOL-Index: 14275

      Fatigue has been shown to be a consistent and common problem in Parkinson's disease (PD) in multiple countries and cultures. It is one of the most disabling of all symptoms, including motor dysfunction, and appears early, often predating the onset of motor symptoms. Several studies of the epidemiology of fatigue have been published, often using different scales, but few on treatment. The Movement Disorder Society (MDS) commissioned a task force to assess available clinical rating scales, ...

      Known for Rating Scales | Task Force | Fatigue Severity | Movement Disorders | Parkinsons Disease
      KOL-Index: 13821

      BACKGROUND: Whether Parkinson disease (PD) and dementia with Lewy bodies (DLB) represent 2 distinct nosologic entities or are diverse phenotypes of Lewy body disease is subject to debate.

      OBJECTIVES: To determine the accuracy of the diagnoses of Lewy body disease, PD, and DLB by validating the clinical diagnoses of 6 neurologists with the neuropathologic findings and to identify early predictors of the diagnoses.

      METHODS: Six raters who were unaware of the neuropathologic diagnoses ...

      Known for Lewy Body Disease | Diagnosis Dlb | Clinical Diagnoses | Clinicopathologic Study | Aged Parkinson
      KOL-Index: 13609

      This article presents the revision process, major innovations, and clinimetric testing program for the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS), known as the MDS-UPDRS. The UPDRS is the most widely used scale for the clinical study of Parkinson's disease (PD). The MDS previously organized a critique of the UPDRS, which cited many strengths, but recommended revision of the scale to accommodate new advances and to resolve ...

      Known for Clinimetric Testing | Movement Disorder Society | Rating Scale | Unified Parkinson | Mdsupdrs Updrs
      KOL-Index: 13263

      The objective of this study is to assess the association between tic severity, attention deficit disorder, obsessive-compulsive behavior, and quality of life (QOL) in children with Gilles de la Tourette syndrome (GTS). GTS is a multidimensional disorder with disturbances in motor function and behavior. However, little is known about what variables are associated with QOL in these patients. We evaluated 56 outpatients with a diagnosis of GTS. The mean age was 10 (range 5-17 years). Tics ...

      Known for Life Qol | Tic Severity | Tourette Syndrome Gts | Disorder Adhd | Hyperactivity Child Child
      KOL-Index: 13194

      BACKGROUND: Older people frequently have signs of parkinsonism, but information about the prevalence of parkinsonism and mortality among those with the condition in the community is limited.

      METHODS: A stratified random sample of 467 residents of East Boston, Massachusetts, 65 years of age or older, were given structured neurologic examinations. Using uniform, specified combinations of parkinsonian signs, we estimated the prevalence of four categories of signs--bradykinesia, gait ...

      Known for Older People | Parkinsonian Signs | Prevalence Parkinsonism | Gait Disturbance | Risk Death
      KOL-Index: 12140

      The recently proposed Movement Disorder Society (MDS) Task Force diagnostic criteria for mild cognitive impairment in Parkinson's disease (PD-MCI) represent a first step toward a uniform definition of PD-MCI across multiple clinical and research settings. However, several questions regarding specific criteria remain unanswered, including optimal cutoff scores by which to define impairment on neuropsychological tests. Seventy-six non-demented PD patients underwent comprehensive ...

      Known for Cognitive Impairment | Task Force | Cutoff Scores | Neuropsychological Tests | Disorder Society
      KOL-Index: 12101

      OBJECTIVE: To prospectively assess the relationship of hallucinations to sleep disorders in patients with Parkinson disease (PD) over 6 years.

      BACKGROUND: Several studies suggest an association between hallucinations and sleep disruption, but no longitudinal study has examined their progression and relationship, nor whether sleep alterations predict future hallucinations.

      METHODS: Eighty-nine PD patients were recruited to fill cells of normal sleep without hallucinations (n = 20); sleep ...

      Known for Sleep Disorders | Vivid Dreams Nightmares | Hallucinations Insight | Patients Parkinson Disease | Longitudinal Studies
      KOL-Index: 12094

      To improve the specificity and sensitivity of the clinical diagnosis of progressive supranuclear palsy (PSP, Steele-Richardson-Olszewski syndrome), the National Institute of Neurological Disorders and Stroke (NINDS) and the Society for PSP, Inc. (SPSP) sponsored an international workshop to develop an accurate and universally accepted set of criteria for this disorder. The NINDS-SPSP criteria, which were formulated from an extensive review of the literature, comparison with other ...

      Known for Criteria Psp | Progressive Supranuclear | Olszewski Syndrome | Year Onset | Prominent Postural Instability
      KOL-Index: 11919

      The objective of this study is to conduct a dose-finding study of sarizotan in Parkinson's disease (PD) patients with dyskinesia to identify a safe dose and to identify a sensitive dyskinesia rating measure. Sarizotan is a novel compound with full 5-HT(1A) agonist properties and additional high affinity for D(3) and D(4) receptors. An open label study documented improvements in PD patients with levodopa-induced dyskinesia. There is no precedent for study designs or outcome measures in ...

      Known for Patients Dyskinesia | Updrs Items | D4 Receptors | Parkinsons Disease | Additional Affinity
      KOL-Index: 11666

      BACKGROUND: Daytime and nighttime sleep disturbances and cognitive impairment occur frequently in Parkinson's disease (PD), but little is known about the interdependence of these non-motor complications. Thus, we examined the relationships among excessive daytime sleepiness, nighttime sleep quality and cognitive impairment in PD, including severity and specific cognitive deficits.

      METHODS: Ninety-three PD patients underwent clinical and neuropsychological evaluations including the ...

      Known for Daytime Sleepiness | Cognitive Status | Nighttime Sleep | Executive Function | Ess Scores
      KOL-Index: 11608

      Drug-induced dyskinesia is a common phenomenon in Parkinson's disease (PD) and is often socially as well as physically disabling for patients. The Movement Disorders Society commissioned a task force to assess available clinical rating scales, critique their clinimetric properties, and make recommendations regarding their clinical utility. A task force composed six clinical researchers who systematically searched the literature for scales measuring dyskinesia in PD, evaluated the scales' ...

      Known for Task Force | Rating Scales | Illness Surveys | Parkinson Disease | Dyskinesia Scale
      KOL-Index: 11254

      Diffusion tensor imaging could be useful in characterizing movement disorders because it noninvasively examines multiple brain regions simultaneously. We report a multitarget imaging approach focused on the basal ganglia and cerebellum in Parkinson's disease, parkinsonian variant of multiple system atrophy, progressive supranuclear palsy, and essential tremor and in healthy controls. Seventy-two subjects were studied with a diffusion tensor imaging protocol at 3 Tesla. Receiver operating ...

      Known for Essential Tremor | Atypical Parkinsonism | Diffusion Tensor Imaging | Parkinsons Disease | Multiple Atrophy

      Key People For Parkinson Disease

      Top KOLs in the world
      #1
      Andrew John Andrew
      parkinsons disease progressive supranuclear motor fluctuations
      #2
      Anthony Edward Lang
      parkinson disease movement disorders subthalamic nucleus
      #3
      Werner H Poewe
      parkinson disease multiple atrophy restless legs syndrome
      #4
      Christopher G Goetz
      parkinson disease movement disorders rating scales
      #5
      Charles W Olanow
      parkinson disease oxidative stress motor complications
      #6
      Joseph J Jankovic
      movement disorders parkinson disease essential tremor

      Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA. | Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States. | Rush University Medical Center, Chicago, Illinois, USA | Rush

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.